Previous clinical studies have demonstrated that endotoxin/toll-like receptor 4 (TLR4) signaling is critical in the inflammatory pathways associated with non-alcoholic steatohepatitis (NASH). Here, TLR4 is linked to metabolic dysfunction-associated steatohepatitis.